KNOWPIA
WELCOME TO KNOWPIA
List of investigational sex-hormonal agents 
Summary
This is a list of investigational sex-hormonal agents, or sex-hormonal agents that are currently under development for clinical use but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.
Androgenics edit
Androgen receptor agonists edit
- EC586 – oral prodrug of testosterone (androgen/anabolic steroid) with improved pharmacokinetics[1][2]
Selective androgen receptor modulators edit
- DT-200 (G-100192, GLPG-0492) – selective androgen receptor modulator for Duchenne muscular dystrophy [1]
- Enobosarm (ostarine; GTx-024, MK-2866; S-22; VERU-024) – selective androgen receptor modulator for breast cancer [2]
- GSK-2881078 – selective androgen receptor modulator for cachexia [3]
- OPK-88004 (LY-2452473; OPK-88004; TT-701) – selective androgen receptor modulator for benign prostatic hyperplasia, erectile dysfunction, and prostate cancer [4]
- VK-5211 (LGD-4033; ligandrol) – selective androgen receptor modulator for hip fracture and muscle atrophy [5]
- Vosilasarm (EP-0062, RAD-140; testolone) – selective androgen receptor modulator for breast cancer [6]
Androgen receptor antagonists edit
- Bavdegalutamide (AVR-110) – androgen receptor antagonist for prostate cancer[7][3][8]
- Clascoterone (CB-03-01, Breezula, Winlevi) – androgen receptor antagonist for topical treatment of scalp hair loss [9]
- Deutenzalutamide (deuterated enzalutamide; HC-1119) – androgen receptor antagonist for prostate cancer [10] [11] [12]
- Pruxelutamide (GT-0918; proxalutamide) – androgen receptor antagonist for prostate cancer [13][4]
- Pyrilutamide (KX-826) – androgen receptor antagonist for topical treatment of androgen-dependent scalp hair loss and acne[5]
- Spironolactone (Aldactone) – androgen receptor antagonist for systemic treatment of acne[14][6][15][7][16]
Atypical androgen receptor antagonists edit
- Dimethylcurcumin (ASC-J9) – androgen receptor degradation enhancer for topical acne treatment [17]
- EPI-7386 – N-terminal domain androgen receptor antagonist for prostate cancer [18] [19] [https://www.prnewswire.com/news-releases/essa-pharma-announces-nomination-of-epi-7386-as-lead-clinical-candidate-in-metastatic-castration-resistant-prostate-cancer-300820449.html
Androgen synthesis inhibitors edit
- Seviteronel (VT-464) – CYP17A1 inhibitor (androgen synthesis inhibitor) for prostate cancer and breast cancer [20]
Estrogenics edit
Estrogen receptor agonists edit
- EC508 – oral prodrug of estradiol (estrogen) with improved pharmacokinetics[1][8][2]
- Erteberel (LY-500307, SERBA-1) – selective ERβ agonist for schizophrenia [21]
- Estetrol (Donesta) – estrogen for menopausal symptoms and other indications [22]
Selective estrogen receptor modulators edit
- Acolbifene (EM-652, SCH-57068) – selective estrogen receptor modulator for breast cancer [23]
- Afimoxifene (4-hydroxytamoxifen; 4-OHT; TamoGel) – selective estrogen receptor modulator for topical treatment of breast cancer and hyperplasia [24]
- Amcenestrant (SAR-439859; SERD '859) – selective estrogen receptor modulator and selective estrogen receptor degrader for breast cancer [25]
- Camizestrant (AZ14066724, AZD-9833) – selective estrogen receptor modulator and selective estrogen receptor degrader for breast cancer [26]
- Endoxifen (4-hydroxy-N-desmethyltamoxifen) – selective estrogen receptor modulator for breast cancer [27]
- Giredestrant (GDC-9545; RG-6171) – selective estrogen receptor modulator and selective estrogen receptor degrader for breast cancer [28]
- Imlunestrant (LY-3484356) – selective estrogen receptor modulator and selective estrogen receptor degrader for breast cancer and endometrial cancer [29]
- Rintodestrant (G1T-48) – selective estrogen receptor modulator and selective estrogen receptor degrader for breast cancer [30]
Estrogen receptor antagonists edit
- Fulvestrant-3 boronic acid (ZB716) – estrogen receptor antagonist (antiestrogen) for breast cancer[9][10]
Estrogen synthesis inhibitors edit
- Estradiol sulfamate (E2MATE, J995, PGL-2, PGL-2001, ZK-190628) – steroid sulfatase inhibitor (estrogen "activation" inhibitor) for endometriosis [31]
- Leflutrozole (BGS-649) – aromatase inhibitor (estrogen synthesis inhibitor) for male hypogonadism [32]
Progestogenics edit
Progesterone receptor agonists edit
- Hydroxyprogesterone caproate (LPCN-1107) – oral progesterone receptor agonist (progestogen/progestin) for prevention of preterm labor[11]
- VOLT-02 – water-soluble conjugate of progesterone and neurosteroid for traumatic brain injury and gynecological disorders [33]
Selective progesterone receptor modulators edit
- Telapristone (CDB-4124, Proellex, Proellex-V, Progenta) – selective progesterone receptor modulator for breast cancer, endometriosis, and uterine fibroids [34]
- Vilaprisan (BAY-1002670) – selective progesterone receptor modulator for endometriosis and uterine fibroids [35]
Progesterone receptor antagonists edit
- Onapristone (AR-18, IVV-1001, ZK-299, ZK-98299) – progesterone receptor antagonist (antiprogestogen) for prostate cancer [36]
GnRH/gonadotropins edit
Kisspeptin receptor agonists edit
- MVT-602 (RVT-602, TAK-448) – small-molecule kisspeptin receptor agonist for female infertility and hypogonadism [37]
Neurokinin/tachykinin receptor antagonists edit
- Elinzanetant (BAY-3427080; GSK-1144814; NT-814) – small-molecule NK1 receptor and NK3 receptor antagonist for hot flashes and "sex hormone disorders"[38]
Mixed/combinations edit
Androgen and progesterone receptor modulators edit
- 11β-Methyl-19-nortestosterone dodecylcarbonate (CDB-4754) – dual androgen/anabolic steroid and progestin for use as a male birth control pill[12]
- Dimethandrolone undecanoate (CDB-4521) – dual androgen/anabolic steroid and progestin for use as a male birth control pill[13]
Androgen and estrogen receptor modulators edit
- Acolbifene/prasterone (Femivia) – selective estrogen receptor modulator and dehydroepiandrosterone supplement for hot flashes [39]
Androgen, estrogen, and progesterone receptor modulators edit
- Ethinylestradiol/drospirenone/prasterone – estrogen, progestogen, and dehydroepiandrosterone combination for female birth control [40]
See also edit
References edit
- ^ a b "R&D Research". www.evestra.com. Archived from the original on 2017-09-29.
- ^ a b Ahmed G, Elger W, Meece F, Nair HB, Schneider B, Wyrwa R, Nickisch K (October 2017). "A prodrug design for improved oral absorption and reduced hepatic interaction". Bioorg. Med. Chem. 25 (20): 5569–5575. doi:10.1016/j.bmc.2017.08.027. PMID 28886996.
- ^ Zeng S, Huang W, Zheng X, Liyan C, Zhang Z, Wang J, Shen Z (January 2021). "Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges". Eur J Med Chem. 210: 112981. doi:10.1016/j.ejmech.2020.112981. PMID 33160761. S2CID 226287993.
- ^ Tong, Youzhi; Chen, Chunyun; Wu, Juan; Yang, Jiangtao; Zhang, Huihui; Wu, Xiaojun; Duan, Yanmei; Gao, Wei; Qian, Weidong; Niu, Xiaoxia; Mi, Lili; Guo, Chuangxing (2014). "Abstract 614: Proxalutamide (GT0918), a potent androgen receptor pathway inhibitor". Cancer Research. 74 (19 Supplement): 614. doi:10.1158/1538-7445.AM2014-614. ISSN 0008-5472.
- ^ "Pyrilutamide - Suzhou Kintor Pharmaceuticals". AdisInsight. Springer Nature Switzerland AG.
- ^ Renz S, Chinnery F, Stuart B, Day L, Muller I, Soulsby I, Nuttall J, Thomas K, Thomas KS, Sach T, Stanton L, Ridd MJ, Francis N, Little P, Eminton Z, Griffiths G, Layton AM, Santer M (August 2021). "Spironolactone for adult female acne (SAFA): protocol for a double-blind, placebo-controlled, phase III randomised study of spironolactone as systemic therapy for acne in adult women". BMJ Open. 11 (8): e053876. doi:10.1136/bmjopen-2021-053876. PMC 8395279. PMID 34446504.
- ^ Poinas A, Lemoigne M, Le Naour S, Nguyen JM, Schirr-Bonnans S, Riche VP, Vrignaud F, Machet L, Claudel JP, Leccia MT, Hainaut E, Beneton N, Dert C, Boisrobert A, Flet L, Chiffoleau A, Corvec S, Khammari A, Dréno B (June 2020). "FASCE, the benefit of spironolactone for treating acne in women: study protocol for a randomized double-blind trial". Trials. 21 (1): 571. doi:10.1186/s13063-020-04432-w. PMC 7318446. PMID 32586344.
- ^ Elger W, Wyrwa R, Ahmed G, Meece F, Nair HB, Santhamma B, Killeen Z, Schneider B, Meister R, Schubert H, Nickisch K (January 2017). "Estradiol prodrugs (EP) for efficient oral estrogen treatment and abolished effects on estrogen modulated liver functions". J. Steroid Biochem. Mol. Biol. 165 (Pt B): 305–311. doi:10.1016/j.jsbmb.2016.07.008. PMID 27449818. S2CID 26650319.
- ^ Liu J, Zheng S, Akerstrom VL, Yuan C, Ma Y, Zhong Q, Zhang C, Zhang Q, Guo S, Ma P, Skripnikova EV, Bratton MR, Pannuti A, Miele L, Wiese TE, Wang G (2016). "Fulvestrant-3 Boronic Acid (ZB716): An Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD)". J. Med. Chem. 59 (17): 8134–40. doi:10.1021/acs.jmedchem.6b00753. PMC 5499704. PMID 27529700.
- ^ Wang, G; Liu, J; Zheng, S; Miele, L; Wiese, T; Zhong, Q; Guo, S (2017). "Abstract P2-08-11: An orally bioavailable selective estrogen receptor downregulator". Cancer Research. 77 (4 Supplement): P2-08-11–P2-08-11. doi:10.1158/1538-7445.SABCS16-P2-08-11. ISSN 0008-5472.
- ^ "Hydroxyprogesterone - Lipocine - AdisInsight".
- ^ "Second potential male birth control pill passes human safety tests".
- ^ "Dimethandrolone undecanoate shows promise as a male birth control pill".
External links edit
- AdisInsight - Springer
- 2011 Medicines in Development for Women - PhRMA